Provider review
Revive Longevity review
By The Dose Brief Desk · Updated
Revive gives tirzepatide buyers a clear recurring-versus-one-time purchase choice; the subscription runs every four weeks.
Not rated. This review examines published program information; it is not a firsthand treatment review.
At a glance
- Semaglutide
- Current semaglutide offering not verified
- Tirzepatide
- $279 every four weeks subscription; $299 one-month or $749 three-month one-time options
- Availability
- Advertises all 50 states; clinical and product eligibility still apply.
- Treatment formats
- Compounded tirzepatide injections.
Four-week subscription billing differs from calendar-month billing; one-time alternatives are separately listed.
Choose the payment model as well as the medication
Revive Longevity’s tirzepatide page lists a $279 subscription every four weeks, a $299 one-month one-time purchase and a $749 three-month one-time option. The differences are useful: someone prioritizing flexibility can compare an explicit nonrecurring purchase against the subscription.
Four-week billing changes an annual budget
Every four weeks means thirteen billing periods in 52 weeks, rather than twelve calendar-month charges. Use the actual cadence when comparing costs. For the three-month option, confirm the supply and delivery schedule rather than assuming three monthly payments.
Payment follows clinical approval
The page says a payment authorization is taken first and the charge follows licensed-provider approval. It describes clinical review and shipping within the offer. This does not guarantee a prescription; the clinician still needs to decide whether the treatment is appropriate.
Canceling future orders is a separate issue
Confirm how to stop the next subscription refill and when pharmacy processing makes an existing order noncancelable. The assigned pharmacy was not established by the reviewed page. A semaglutide program was also not verified, so the tirzepatide options should be compared on their own.
What stands out
- Explicit one-time and subscription alternatives
- Four-week cadence is disclosed
What to check
- Subscription has thirteen periods per 52 weeks
- Pharmacy assignment and processing cutoff need confirmation
Sources and review scope
Public information checked in October 2026. Prices and eligibility can change. We have not enrolled in treatment, independently tested medications or verified the licenses of the clinicians and pharmacies involved in an individual prescription. Compounded medications are not FDA-approved; studies of approved brands do not establish that a compounded product has the same safety or effectiveness.